Pulmatrix Inc is a clinical-stage biotechnology company. The company is focused on the discovery and development of novel inhaled therapeutic products intended to prevent and treat respiratory diseases and infections with significant unmet medical needs. Pulmatrix designs and develops inhaled therapeutic products based on its proprietary dry powder delivery technology, iSPERSE (inhaled Small Particles Easily Respirable and Emitted), which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. The iSPERSE powders are engineered to be small, dense particles with dispersibility and delivery to airways.
Quote | Pulmatrix Inc. (NASDAQ:PULM)
Last: | $2.1291 |
---|---|
Change Percent: | -0.28% |
Open: | $2.08 |
Close: | $2.135 |
High: | $2.14 |
Low: | $2.06 |
Volume: | 3,022 |
Last Trade Date Time: | 07/30/2024 03:00:00 am |
News | Pulmatrix Inc. (NASDAQ:PULM)
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation PR Newswire Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket ® inhalation device. Pulmatrix transferring leased building,...
2024-05-17 16:30:05 ET More on Pulmatrix Financial information for Pulmatrix Read the full article on Seeking Alpha For further details see: Pulmatrix files for $95M mixed shelf
Message Board Posts | Pulmatrix Inc. (NASDAQ:PULM)
Subject | By | Source | When |
---|---|---|---|
bears are running | Value_Investor | investorshub | 05/11/2023 2:25:52 AM |
Anyone hear anything lately? Want to see this one go | riskon | investorshub | 05/11/2023 1:55:09 AM |
$PULM MomentumIts gaining up | Value_Investor | investorshub | 05/09/2023 7:43:19 PM |
Price trading up | lakerol | investorshub | 05/08/2023 8:34:55 AM |
where is the squeeze? | makinezmoney | investorshub | 05/06/2023 4:35:26 PM |
News, Short Squeeze, Breakout and More Instantly...
Pulmatrix Announces Cross License Agreement and Transfer of Laboratory to MannKind Corporation PR Newswire Cross license involves Pulmatrix iSPERSE™ technology and MannKind's Cricket ® inhalation device. Pulmatrix transferring leased building,...
Pulmatrix Announces Peer-Reviewed Publication of Clinical Results for its Orally Inhaled DHE for Acute Migraine (PUR3100) PR Newswire Orally Inhaled PUR3100 is associated with rapid systemic PK within the therapeutic window and a mean time to Cmax matching intravenously (IV) a...